Johnson & Johnson (NYSE:JNJ) will release earnings for its third quarter before the opening bell on Tuesday, Oct. 13.
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings of $2.48 per share, down from $2.80 per share in the year-ago period. The consensus estimate for JNJ’s quarterly revenue is $25.31 billion. It reported $23.99 billion last year, according to Benzinga Pro.
On Sept. 25, Johnson & Johnson announced positive findings from key clinical evaluations testing its therapies, Tremfya and Carvykti, across psoriatic arthritis and multiple myeloma.
Shares of Johnson & Johnson fell 1.6% to close at $267.57 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- JP Morgan analyst Chris Scott maintained a Neutral rating and raised the price target from $270 to $285 on Sept. 29, 2026. This analyst has an accuracy rate of 67%.
- HSBC analyst Rajesh Kumar maintained a Buy rating and increased the price target from $290 to $320 on Sept. 10, 2026. This analyst has an accuracy rate of 57%.
- UBS analyst Michael Yee maintained a Buy rating and boosted the price target from $280 to $320 on Sept. 2, 2026. This analyst has an accuracy rate of 66%.
- Guggenheim analyst Vamil Divan maintained a Buy rating and raised the price target from $270 to $287 on Aug. 6, 2026. This analyst has an accuracy rate of 79%.
- Wells Fargo analyst Larry Beigelsen maintained an Overweight rating and increased the price target from $272 to $282 on Aug. 3, 2026. This analyst has an accuracy rate of 64%.
Considering buying JNJ stock? Here’s what analysts think:
Photo via Shutterstock